365telugu.com online news,India,December1, 2025: SAI Parenteral’s Limited (SPL), a diversified pharmaceutical formulation company, has announced a significant expansion into global markets by acquiring a 74.6% controlling stake in Noumed Pharmaceuticals Pty Ltd. The Adelaide-based pharmaceutical company was acquired for an aggregate sum of INR 125 crore (approximately USD $15 million).
This acquisition marks a pivotal moment for SPL, which recently filed its Draft Red Herring Prospectus (DRHP) with SEBI on September 30, 2025, for an Initial Public Offering (IPO). The proposed IPO includes a fresh issue of up to INR 285 crore and an Offer for Sale of up to 3,500,000 equity shares.
Noumed: A Strategic Gateway to Regulated Markets
Noumed Pharmaceuticals, with a current annual revenue of AUD 60 million, specializes in supplying private label Over-The-Counter (OTC) products to major pharmacy chains across Australia and New Zealand.
Key strategic assets of the acquisition include:
Extensive Portfolio: Noumed holds a strong portfolio of over 451 product dossiers, providing broad coverage across numerous therapeutic categories.
New Manufacturing Facility: The company is currently investing AUD 53 million to establish a modern manufacturing facility in Adelaide, which is slated to begin commercial operations by the fourth quarter of CY 2026.
Synergies and Future Growth
Anil KK, Managing Director of SAI Parenteral’s Limited, stated that the acquisition is a “transformative milestone” aimed at establishing SPL as a global, innovation-led formulations and CDMO (Contract Development and Manufacturing Organization) platform.
“By combining Noumed’s R&D capabilities, distribution network, extensive dossier library, and upcoming manufacturing facility, along with SAI Parenterals’ strengths and capabilities in India, we are unlocking significant synergies across the value chain,” he commented.
The partnership is expected to enhance SPL’s entry into regulated and semi-regulated markets, strengthening its revenue quality and visibility through Noumed’s established customer relationships and long-term supply contracts.
Mark Thulborne, Managing Director of Noumed Pharmaceuticals Pty Ltd, expressed confidence in the collaboration: “This strategic partnership will accelerate our product pipeline, benefit from SAI’s manufacturing capabilities, and help us meet the growing demand in the Australian, New Zealand, and global markets.”
SAI Parenteral’s is currently supported by marquee investors, including Gruhas, Samarsh Capital, Vyom Partners, and Blue Lotus Capital.